Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Print1
- Journal1
- Article Type
- Clinical Trial1
- Clinical Study1
- Comparative Study1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Lancet1
Search Results
Sort by
- Journal
- ArticleNicholson KG, Tyrrell DA, Freestone DS.Lancet. 1976 Jun 19;1(7973):1309-11.The acceptability, reactivity, and antibody responses of recombinant WRL 105 strain, live, attenuated influenza virus vaccine administered intranasally were studied in seventeen normal adults, and in seventeen bronchitic and twenty-one geriatric volunteers. The effect on peak flow and 1-second forced expiratory volume (F.E.V.1) on the 3rd, 5th, and 7th days after vaccination was measured in the bronchitic and normal groups. Seroconversion occurred in 80% to tht homologous virus, in 40.6% to A/Victoria/3/75, and in 26.5% to A/England/864/75 in subjects with pre-vaccination haemagglutination inhibition titres of less than 1/40. A fourfold or greater increase in homologous anti-neuraminidase antibody was found in 48% of twenty-seven infected subjects when measured by a new elution inhibition technique. The frequency and nature of symptoms were similar in both infected and non-infected groups. No significant changes in F.E.V.1 occurred, but on days 5 and 7 there was a decrease in peak flow measurements in both infected and non-infected groups when assessed as the percentage change of the pre-vaccination value.